NCT04675008Unknown2 期
A Phase II Study of Dacomitinib in Advanced Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer (NSCLC) Patients Who Have Non-irradiated Brain Metastasis
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- CNS objective response rate (Complete response or Partial response)
研究概览
简要总结
This is a single-arm, phase II study of dacomitinib in advanced EGFR-mutant NSCLC patients who have non-irradiated brain metastasis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Biopsy proven recurrent or metastatic NSCLC (adenocarcinoma) with major EGFR mutation (exon 19 deletion or Leu858Arg mutation without the Thr790Met)
- •No prior systemic treatment of advanced NSCLC (Neoadjuvant or adjuvant chemotherapy are allowed, without limitation on its treatment timing)
- •Age ≥20 years
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1
- •Had at least one measurable intracranial lesion as ≥ 5mm in the longest diameter by magnetic resonance imaging (MRI) (≥ 5mm by thin section (1.2mm) of brain MRI image, ≥ 10mm by less thin section(2.5mm) brain MRI ), which checked within 4 weeks before enrollment. If MRI slice thickness is not appropriate, we need to recheck Brain MRI
- •Number of brain metastasis =>5
- •Adequate organ function
- •Female subjects must either be of non-reproductive potential
- •Subject is willing and able to comply with the protocol
- •Signed written informed consent
排除标准
- •Severe symptomatic brain metastasis, needing urgent control with radiotherapy or high dose steroid: the definition of high dose steroid is the equivalent dose of dexamethasone 10 mg or higher per day (mild symptoms controlled with low dose of steroid can be enrolled)
- •With leptomeningeal seeding
- •Exposure to EGFR-TKIs or other EGFR targeting agents at any time in either neoadjuvant or adjuvant setting
- •Local treatment (stereotatic radiosurgery or whole brain radiotherapy) for brain metastases
- •Uncontrolled systemic illness including uncontrolled hypertension, active bleeding, or active infection.
- •Past medical history of interstitial lung disease, drug induced interstitial lung disease, radiation pneumonitis which required steroid treatment
- •Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
- •Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
研究组 & 干预措施
Study arm
Experimental
Dacomitinib
干预措施: Dacomitinib (Drug)
结局指标
主要结局
CNS objective response rate (Complete response or Partial response)
时间窗: 1 year
The rate of CR or PR of CNS disease
次要结局
- CNS progression-free survival(1 year)
- Cumulative incidence of CNS failure by competing risk analysis(1 year)
- Safety by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0(1 year)
- Extracranial objective response rate(1 year)
- Progression-free survival(1 year)
- Overall survival(1 year)
研究者
Jong-Mu Sun
Associated Professor
Samsung Medical Center
研究点 (1)
Loading locations...
相似试验
已完成
不适用
A phase II study of dacomitinib in advanced EGFR-mutant non-small cell lung cancer (NSCLC) patients who have non-irradiated brain metastasisNeoplasmsKCT0005748Samsung Medical Center30
Unknown
2 期
An Open Label, Multicenter, Phase II Study of Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain MetastasesDacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain MetastasesNCT04339829Guangdong Association of Clinical Trials50
终止
2 期
Phase II Study of Dasatinib in Previously Treated Patients With Advanced NSCLCNon Small Cell Lung CancerNCT00787267Duke University37
Unknown
2 期
EGFR Mutation Positive NSCLC Patients With Gefitinib and ThalidomideNSCLC Stage IVChemotherapy EffectNCT03341494Fujian Cancer Hospital128
进行中（未招募）
2 期
Dacomitinib in Lung Cancer With Uncommon EGFR MutationsNon-small Cell Lung Cancer MetastaticEGF-R Positive Non-Small Cell Lung CancerNCT04504071Shanghai Chest Hospital30